Theravance Biopharma, Inc. (TBPH)
17.08
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
17.08
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Research and Development Expense (Quarterly) : 4.345M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.345M |
| March 31, 2026 | 5.448M |
| December 31, 2025 | 6.963M |
| September 30, 2025 | 7.707M |
| June 30, 2025 | 10.08M |
| March 31, 2025 | 11.04M |
| December 31, 2024 | 9.14M |
| September 30, 2024 | 8.839M |
| June 30, 2024 | 9.527M |
| March 31, 2024 | 8.536M |
| December 31, 2023 | 8.023M |
| September 30, 2023 | 7.879M |
| June 30, 2023 | 8.873M |
| March 31, 2023 | 13.95M |
| December 31, 2022 | 15.35M |
| September 30, 2022 | 9.212M |
| June 30, 2022 | 13.96M |
| March 31, 2022 | 22.27M |
| December 31, 2021 | 31.22M |
| September 30, 2021 | 42.11M |
| June 30, 2021 | 49.71M |
| March 31, 2021 | 67.60M |
| December 31, 2020 | 65.16M |
| September 30, 2020 | 67.37M |
| June 30, 2020 | 62.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 66.01M |
| December 31, 2019 | 65.26M |
| September 30, 2019 | 50.20M |
| June 30, 2019 | 46.40M |
| March 31, 2019 | 53.82M |
| December 31, 2018 | 52.27M |
| September 30, 2018 | 52.69M |
| June 30, 2018 | 48.62M |
| March 31, 2018 | 47.76M |
| December 31, 2017 | 51.05M |
| September 30, 2017 | 39.34M |
| June 30, 2017 | 42.93M |
| March 31, 2017 | 40.56M |
| December 31, 2016 | 42.01M |
| September 30, 2016 | 31.95M |
| June 30, 2016 | 32.07M |
| March 31, 2016 | 35.68M |
| December 31, 2015 | 32.40M |
| September 30, 2015 | 30.37M |
| June 30, 2015 | 30.38M |
| March 31, 2015 | 36.02M |
| December 31, 2014 | 42.19M |
| September 30, 2014 | 38.32M |
| June 30, 2014 | 45.60M |
| March 31, 2014 | 41.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Zymeworks, Inc. | 27.44M |
| Viatris, Inc. | 245.20M |
| Ocular Therapeutix, Inc. | 54.14M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |